* UNITY Biotechnology Inc UBX.OQ reported a quarterly
adjusted
loss of 85 cents per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 86 cents per share.
* Reported revenue was zero; analysts expected zero.
* UNITY Biotechnology Inc's reported EPS for the quarter was
a
loss of 85 cents.
* The mean earnings estimate of analysts had risen by
about 18.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* UNITY Biotechnology Inc shares had fallen by 9.8% this
quarter and lost 16.1% so far this year.
* The company reported a quarterly loss of $12.21 million.
* Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $8.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
August 10 at 12:06 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2023 -0.86 -0.85 Beat
Mar. 31 2023 -1.08 -0.76 Beat
Dec. 31 2022 -1.05 -1.00 Beat
Sep. 30 2022 -1.65 -1.36 Beat